Vol 26, No 2 (2019)
Letters to the Editor — Interventional cardiology
Published online: 2019-04-26

open access

Page views 1229
Article views/downloads 848
Get Citation

Connect on Social Media

Connect on Social Media

Fully bioresorption of an Absorb bioresorbable vascular scaffold after scaffold restenosis

Luis R. Goncalves-Ramírez1, Hipólito Gutiérrez12, Paol Rojas1, Carlos Cortés1, Ana Serrador12, Benigno Ramos1, Jairo Toro1, Ignacio J. Amat-Santos12, José A. San Román12
Pubmed: 31032876
Cardiol J 2019;26(2):209-211.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Byrne RA, Stefanini GG, Capodanno D, et al. Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. EuroIntervention. 2018; 13(13): 1574–1586.
  2. Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013; 6(10): 999–1009.
  3. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373(9667): 897–910.
  4. Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv. 2015; 8(1 Pt B): 189–197.
  5. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015; 385(9962): 43–54.
  6. Wykrzykowska J, Kraak R, Hofma S, et al. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med. 2017; 376(24): 2319–2328.
  7. Stone GW, Gao R, Kimura T, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016; 387(10025): 1277–1289.
  8. Gutiérrez-Chico JL, Cortés C, Schincariol M, et al. Implantation of bioresorbable scaffolds under guidance of optical coherence tomography: feasibility and pilot clinical results of a systematic protocol. Cardiol J. 2018 [Epub ahead of print].
  9. Karanasos A, Simsek C, Gnanadesigan M, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2014; 64(22): 2343–2356.
  10. Suwannasom P, Sotomi Y, Asano T, et al. Change in lumen eccentricity and asymmetry after treatment with Absorb bioresorbable vascular scaffolds in the ABSORB cohort B trial: a five-year serial optical coherence tomography imaging study. EuroIntervention. 2017; 12(18): e2244–e2252.